Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dana-Farber Cancer Institute
With
Prostate Cancer Foundation
This research study seeks to develop and evaluate a mobile health app which aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habits. The first phase of the research study seeks to evaluate the experience of the first version of the mobile health app within a group of participants and what they think of it.
The investigators are interested in how individuals react to the use of a developed mobile health app and what they think of it.
Age
40–75
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Phase 1
All recruited participants must have owned a smartphone for \>1 year
English-speaking.
Patients with prostate cancer aged between 40-75 years will be considered.
No specific timeframe after prostate cancer diagnosis will be required for these patients.
No limitations regarding their disease characteristics will be imposed (e.g. metastatic disease).
Patients may or may not be currently receiving treatment Staff members will be recruited from
Dana-Farber Cancer Institute Department of Medical Oncology,
Brigham and Women's Hospital, Department of Surgery. Staff members aged between 40-75 years old will be considered. Phase 2
Men diagnosed with prostate cancer presenting to DF/BWHCC
About to initiate ADT for the first time will be considered.
Age range 40-75-years
The ability to walk 400 m
Medical clearance from their primary physician
English speaking
Cognitively alert
Literate
Ability to read or hear with or without contacts/glass and hearing aid
Ownership of a smartphone for \>1yr
You may not be if
Men who have been under a rigorous structured exercise regime, such as individuals who engage in more than 900 minutes of moderate physical activity per week in the last 6 months will not be considered
Post-ADT treatment
Planned systemic chemotherapy
Planned treatment with abiraterone or enzalutamide
Bone metastases
Acute illness
Any musculoskeletal, cardiovascular, or neurologic disorders that could inhibit or put them at risk from exercising
